# A Trial of CRD-4730 in HFrEF

Study · id `cardio:ct-nct07750873` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07750873](<https://clinicaltrials.gov/study/NCT07750873>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07750873

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 525 participants.

## Technical summary

Registry record NCT07750873. Randomized; triple masking; primary purpose treatment. Start 2026-07-15 (actual); primary completion 2028-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 525 participants (planned count; ClinicalTrials.gov record NCT07750873, source copy `cardio:ctgov-nct07750873-2026-08-06`, retrieved 2026-10-26)
- Started: 2026-07-15 (actual) (ClinicalTrials.gov record NCT07750873, source copy `cardio:ctgov-nct07750873-2026-08-06`, retrieved 2026-10-26)
- Primary completion: 2028-09 (anticipated) (ClinicalTrials.gov record NCT07750873, source copy `cardio:ctgov-nct07750873-2026-08-06`, retrieved 2026-10-26)
- Completion: 2028-09 (anticipated) (ClinicalTrials.gov record NCT07750873, source copy `cardio:ctgov-nct07750873-2026-08-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07750873, source copy `cardio:ctgov-nct07750873-2026-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07750873-2026-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial of CRD-4730 in HFrEF
- Acronym: CALIBRATE-HF
- Condition: Heart Failure With Reduced Ejection Fraction (HFrEF)
- Intervention (Drug): CRD-4730
- Intervention (Drug): Placebo
- Lead sponsor: Cardurion Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: Cardurion Pharmaceuticals, Inc. (`cardio:org-cardurion-pharmaceuticals-inc`)

## Provenance

Content hash: af90b7b9eb3e65e8d156c26be3344af0f6816ed88254ad84f85dab636e0d4f98
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
